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Abbreviations 
 
 
ALL       Acute lymphoblastic leukaemia 
ERK  Extracellular signal-regulated kinase 
FCS  Foetal calf serum 
GPCR  G protein-coupled receptor 
ICAM-1 Intracellular adhesion molecule-1 
LCD  Low cell density 
LFA-1  Lymphocyte function-associated antigen-1 
PDGF  Platelet-derived growth factor 
 
PI3K  Phosphatidylinositol 3-kinase  
 
SDF-1  Stromal cell-derived factor-1 
 
SLE   Systemic lupus erythmatosus 
 
[3H]  Tritiated thymidine 
 
VCAM-1 Vascular cell adhesion moleucle-1 
 
VLA-4  Very late antigen-4 
 
VLA-5  Very late antigen-5 
VnR  Vitronectin receptor 
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Abstract 
 
CD23 acts via the αvβ5 integrin to promote growth of human pre-B cell lines in an 
adhesion-independent manner. αvβ5 is expressed on normal B cell precursors in the bone 
marrow. Soluble CD23 (sCD23), short CD23-derived peptides containing the arg-lys-cys 
(RKC) motif recognised by αvβ5, and anti- αvβ5 monoclonal antibodies all sustain 
growth of pre-B cell lines. The chemokine SDF-1 regulates key processes during B-cell 
development. SDF-1 enhanced the growth sustaining effect driven by ligation of αvβ5 
with anti- αvβ5 MAb 15F-11, sCD23 or CD23-derived RKC containing peptides. This 
effect was restricted to B-cell precursors and was specific to SDF-1. The enhancement in 
growth was associated with activation of ERK and both these responses were attenuated 
by the MEK inhibitor U0126.  Finally, PDGF also enhanced both αvβ5-mediated cell 
growth and ERK activation. The data suggest that adhesion-independent growth-
promoting signals delivered to B cell precursors via the αvβ5 integrin can be modulated 
by crosstalk with receptors linked to both G-protein and tyrosine kinase-coupled 
signalling pathways. 
 
 3
 Introduction 
 
B lymphopoiesis is a tightly-regulated multi-stage process. The bone marrow 
microenvironment provides a variety of cytokines, chemokines, growth factors and 
adhesion molecules that co-ordinately regulate B cell development.  Perturbation of B 
cell differentiation in the bone marrow leads to malignancies including acute 
lymphoblastic leukemia (ALL) (1). 
 
The interaction between soluble CD23 (sCD23) and the integrin αvβ5 sustains growth of 
human pre-B cell lines derived from ALL patients (2, 3). Human CD23, a 45kDa type II 
transmembrane glycoprotein can be cleaved from the cell surface to release a range of 
sCD23 proteins with cytokine-like activities. The cytokine-like activities include 
promoting the release of cytokines from monocytic cells, mediated via the αMβ2, αXβ2 
(4, 5) and αvβ3 integrins (6), and influencing the survival and differentiation of 
centrocytes via binding to CD21 (7-9).  Plasma sCD23 levels are low in normal subjects, 
but high levels are reported in inflammatory disorders such as rheumatoid arthritis and 
SLE (10). Particularly high levels of sCD23 with prognostic value are a hallmark of B 
cell chronic lymphoblastic leukaemia (11). The αvβ5 integrin, a member of the 
vitronectin receptor (VnR) family, is expressed by bone marrow B cell precursors (2).  
The VnR family members comprise the αv chain in non-covalent association with one of 
five β subunits (β1, β3, β5, β6 and β8) and bind a broad spectrum of ligands, including 
fibrinogen, fibronectin and vitronectin, typically by recognition of arg-gly-asp (RGD) 
motifs (12-14). VnRs have diverse roles in cell adhesion, migration and survival and are 
implicated in growth of number of cancer cells. The VnRs αvβ5 and αvβ3 are recognised 
CD23 receptors (2, 6) and αvβ5 recognises an arg-lys-cys (RKC) motif on sCD23 in an 
adhesion-independent interaction (2).  
 
The growth and survival of normal and leukaemic B cell progenitors is dependent on 
intimate contact with bone marrow stromal layers (15-17) and the factors responsible for 
proliferation of progenitor cells include both cellular adhesion molecules and soluble 
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proteins (15). The αvβ5-CD23 interaction could represent an important mechanism 
regulating the growth of B cell precursors, in combination with other factors present in 
the bone marrow microenvironment.  
 
Stromal cell-derived factor-1 (SDF-1 or CXCL12) is a member of the CXC chemokine 
family (18) that binds to CXCR4 and CXCR7 receptors (19, 20). Gene inactivation of 
SDF-1 or CXCR4 in vivo causes embryonic lethality due to abnormal cerebral and 
gastrointestinal vasculatures and haematopoietic development (21-24). SDF-1 is the most 
powerful chemoattractant for undifferentiated human CD34+ haematopoietic progenitors 
(25, 26). Several studies have shown that SDF-1 activates the integrins LFA-1, VLA-4 
and VLA-5 (27-31), and facilitates transendothelial migration, homing and engraftment 
of precursor B cells in the bone marrow (31, 32). In addition to its established role in 
regulating cell motility, SDF-1 also plays a role in cell survival (33, 34) and proliferation 
(35), often in synergy with other cytokines (36). CXCR4 ligation by SDF-1 induces 
receptor internalisation, elevation of cytoplasmic Ca2+ levels, activation of 
phosphatidylinositol 3-kinase (PI3K), and phosphorylation of MEK, ERK and 
components of focal adhesion complexes in many cell types including B cell precursors 
(37-43).  
 
The well-established role of SDF-1 in B-lymphopoiesis and in influencing integrin 
function, make it an attractive candidate for modulating αvβ5 function. The data in this 
report indicate that SDF-1 modulates the growth-sustaining function of αvβ5, by 
influencing ERK signalling downstream of both CXCR4 and αvβ5; platelet-derived 
growth factor (PDGF) also enhances αvβ5-mediated signalling. PDGF has been 
extensively studied in the context of integrin-growth factor receptor cross-talk (44) and 
we therefore assessed the role of PDGF together with  other cytokines, in modulating 
αvβ5 function. The data demonstrate that biological responses activated via the αvβ5 -
CD23 interactions in early B cell precursors are modulated by inputs from both G-
protein-coupled and tyrosine kinase-linked receptors. 
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Materials and Methods  
 
Antibodies and Reagents 
Recombinant cytokines (IL-7, IL-3, IL-11, IL-4), anti-CXCR7 (clone 358426, IgG2a) 
biotinylated anti-CXCR4 (12G5, IgG2a) antibody, and recombinant human 25kDa 
sCD23, encompassing residues Met151-Ser231 with an N-terminal His6 tag, were purchased 
from R&D Systems, Abingdon, UK. Anti- αvβ5 (P1F6, IgG1; 15F11, IgG2a), biotinyl-
murine IgG1 and recombinant SDF-1β were from Chemicon, Hampshire, UK, and anti-
phospho-p44/42 MAP kinase, anti-p44/42 MAP kinase, PI3K inhibitor LY294002 and 
platelet-derived growth factor (PDGF-B) were supplied by Cell Signalling, Technologies, 
Beverly, MA, USA. Streptavidin-PE, annexinV-FITC, anti-CD19-PE, anti-kappa-FITC 
and anti-CXCR4-PE were from BD Bioscience, Oxford, UK. Isotype control IgG2a 
antibody, anti-actin antibody, horseradish peroxidase (HRP)-conjugated anti-rabbit 
immunoglobulins, AMD3100, propidium iodide (PI) and DMEM (Dulbecco’s Modified 
Eagle Medium) were from the Sigma Chemicals Co, Poole, UK. Biotinylated isotype 
control IgG2a antibody was from Serotec, Oxford, UK.  The MEK inhibitor U0126 was 
purchased from Promega, UK. Tritiated thymidine ([3H]-TdR) was obtained from 
Amersham International plc, Amersham, Buckinghamshire, England.  RPMI-1640 
medium, AIMV serum free medium and protein-free hybridoma medium-II (PFHM) 
were from GIBCO-BRL (Paisley, Scotland). Anti-ERK/2 antibody was purchased from 
Santa Cruz Biotechnology, Inc, California, USA.  
 
 
Cell lines and cell culture  
The SMS-SB cell line was derived from a female patient presenting with acute 
lymphoblastic leukaemia (45); SMS-SB cells were cultured in PFHM supplemented with 
2 mM fresh glutamine and 1% (w/v) penicillin and streptomycin at 37°C in 5% CO2 in air 
in a humidified atmosphere, at 2.5-5 x 105 cells/ml. RS4;11 (46),  Blin-1, RAJI , Daudi 
and  IB4 B cell lines were from laboratory stocks.  Cell lines were maintained in RPMI -
1640 medium supplemented with 10% (v/v) heat-inactivated fetal calf serum, 2 mM fresh 
glutamine, and penicillin and streptomycin, at 37 °C in a 5% CO2 in air in a humidified 
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atmosphere. hMSC-tert telomerised human stromal cell line was a gift from Dr. M 
Kassem (Denmark) (47) and was maintained in DMEM supplemented with 10% (v/v) 
heat-inactivated fetal calf serum, 2 mM fresh glutamine, and penicillin and streptomycin. 
Normal human bone marrow was obtained from Lonza Biologics, Slough, UK.  Aliquots 
were subjected to sterile sorting on a FACSAria instrument (BD Bioscience) using FITC 
anti-κ chain and PE-anti-CD19 MAbs to obtain a fraction of cells enriched for B cell 
precursors.  For cultures with sCD23, peptides and anti-αvβ5 MAbs, the cells were 
propagated in medium supplemented with 2% (v/v) FCS and hMSC-tert stromal cells.  
Mononuclear cells were isolated from samples from ALL patients and were cultured in 
AIMV serum free medium, hMSC-tert stromal cells and stimulants. 
 
Cell Growth Assays  
SMS-SB cells were washed then plated at a density of 2500 cells/100µl culture (low cell 
density (LCD), a seeding density at which the cells are prone to apoptose (3), in 96-well 
microtitre assay plates in PFHM. All other cell lines were washed extensively in PFHM 
prior to culture at 5000 cells/100µl cultures. Cultures were propagated in the presence or 
absence of cytokines, MAbs or peptides, at 37 °C for 72 h followed by addition of 0.3 
µCi/well [3H]-TdR for 18 h prior to harvest; incorporation was determined by liquid 
scintillation spectrometry. For assays with bone marrow B cells or ALL cells, γ-irradiated 
(30 Gy [3000 rad])  hMSC-tert stromal cells were plated at a density of 2 X 105 cells/ 
well at least 7 days prior to addition of mononuclear cells. FACS sorted human bone 
marrow B cells were plated at a density of 3000 cells/ well on the stromal cells in RPMI -
1640 medium supplemented with 2% (v/v) heat-inactivated fetal calf serum, 2 mM fresh 
glutamine, and penicillin and streptomycin. ALL cells were plated at the same cell 
density in AIMV serum-free medium. All cultures were established in triplicate. 
Cytokines were used at 0.5-32nM and sCD23 was employed at 0.4-6nM. In experiments 
using inhibitors, cells were incubated with the inhibitors (5-10µM U0126, 50µM 
LY294002, 50µM AMD3100) for 30 min at 37˚C prior to the introduction of stimuli.  
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Peptide Biochemistry  
CD23-derived peptides containing the RKC motif recognised by the αvβ5 integrin are 
biologically active. The peptides were used at 0.5-3.33µM and are numbered according to 
their position in the original screening library (2). The sequences of the peptides used in 
this study are #9, KWINFQRKC; #11, FQRKCYYFG; LP long peptide,  
KWINFQRKCYYFGKG. Peptides #8, PEKWINFQR; #41, SGSGGEFIWVDGS; and  
#34, SGSGHTGSWIGLR that lack the RKC motif and do not bind to αvβ5 were used as 
negative control peptides. 
 
Flow cytometry 
Cells were harvested and washed twice with ice-cold PBS and resuspended at 5 × 106 
cells/ml. 100µl of cell suspension was stained with either biotinylated, unlabeled primary 
MAb or biotinylated CD23-derived peptides (10µg/ml) for 30-60 min; unlabeled primary 
antibody was visualized using a secondary PE-conjugated anti-mouse IgG or, in the case 
of biotinylated antibody or peptides, streptavidin-PE. For assay of apoptosis, 
approximately 1 X 106 cells were washed twice with ice-cold PBS and stained with 100µl 
labelling buffer (10mM HEPES-KOH, pH 7.4,150mM NaCl, 5mM CaCl2, 0.5µg 
propidium iodide and 5µl annexinV-FITC) and incubated at room temperature for 20 
min. The labelling buffer was aspirated and the cells were resuspended in 400µl wash 
buffer (10mM HEPES-KOH, pH 7.4,150mM NaCl, 5mM CaCl2). Cells were analyzed on 
a FACScan flow cytometer, using CellQuest software.  
 
Western blot analysis 
Approximately 3 x 107 cells in PFHM were stimulated with either SDF-1 (250ng/ml) 
sCD23 (160ng/ml), Long peptide (1µg/ml), Peptide #8 or #9 (5µg/ml), 15F-11 MAb 
(5µg/ml) alone or in combination for specified time periods at 37ºC. Stimulation was 
stopped by addition of RIPA buffer without detergents (50mM Tris-HCl pH7.4, 150mM 
NaCl, 1mM EGTA, 1mM Na3VO4).  Cell pellets were lysed in RIPA buffer containing 
detergents and protease inhibitors (RIPA buffer as above plus 1%  (w/v) NP40, 1mM Na 
deoxycholate, 1mM PMSF and 2μg/ml Leupeptin) and clarified by centrifugation at 
13,000 x g for 15 min. Protein concentrations were determined using the Bradford 
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reagent (BioRad Laboratories Ltd, Hampstead, UK) with BSA as a standard. Equal 
amounts of protein (30-40µg) were loaded per lane on 4-12% NuPAGE Novex Bis-Tris 
polyacrylamide gradient gels (Invitrogen, Paisely, UK) and transferred onto 
nitrocellulose. Phosphorylated and total protein profiles were detected sequentially on the 
same membrane using specific primary antibodies, secondary antibodies conjugated to 
HRP and enhanced chemiluminescence (Pierce, Rockford, USA). Bands were quantified 
by densitometry using ImageJ software. 
 
 
Results  
 
SDF-1 enhances growth of Pre-B cell lines induced by ligation of αvβ5 integrin 
 
The αvβ5-sCD23 interaction sustains growth of human precursor B cell lines (2). CD23-
derived peptides containing the RKC motif recognised by the αvβ5 integrin and the 15F-
11 MAb, which binds the assembled αvβ5 heterodimer, all sustain growth in a manner 
similar to sCD23 (2).  SMS-SB cells treated with sCD23 show a dose-dependent increase 
in [3H]-TdR incorporation (Figure 1A). Other pre-B cell lines such as RS4;11 and 697 
show a similar response to sCD23 stimulation (data not shown). SMS-SB cell growth 
induced by a sub-optimal concentration of sCD23 is enhanced by SDF-1 treatment 
(Figure 1B) in a dose-dependent manner; SDF-1 alone has a minimal effect on growth of 
SMS-SB cells at any concentration used.  Growth of SMS-SB cells stimulated by the 
15F-11 MAb is also enhanced by SDF-1 (Figure 1C) confirming that the growth-
promoting effect is specific to αvβ5 ligation. SDF-1 enhances growth of SMS-SB cells 
stimulated with CD23-derived peptide #9, a nonameric peptide containing the RKC 
motif, but has no effect on the ability of peptide #34, which lacks the RKC tripeptide, to 
promote cell growth (Figure 1D). SDF-1 also enhances cell growth stimulated by the long 
peptide (LP), a particularly potent CD23-derived peptide containing the RKC motif 
(Figure 1E). The CXCR4-specific antagonist AMD3100 was used to inhibit binding of 
SDF-1 to CXCR4.  Figure 1F shows that after AMD3100 treatment there is no difference 
in cell growth induced by LP in the presence or absence of SDF-1 in SMS-SB cells, 
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indicating that the enhancement in LP-induced cell growth is via SDF-1 and CXCR4. 
There was no change is αvβ5 expression in cells treated with SDF-1 compared to 
untreated cells (Figure 1G), nor was there any increase in peptide binding to treated cells 
(Supplementary Figure 1A).  Furthermore, stimulation of αvβ5 with either LP or sCD23 
did not influence CXCR4 expression (Supplementary Figure 1B). While the data 
demonstrate that SDF-1 can cooperate with soluble αvβ5-directed ligands to enhance 
growth of SMS-SB cells, it remains to be determined whether this reflects either 
inhibition of apoptosis, stimulation of cell division or a combination of both processes.  
 
Enhancement of αvβ5-driven cell growth by SDF-1 is specific to B cell precursors 
 
CXCR4 expression varies in cell lines representing distinct stages of B cell development 
(Figure 2A), and a similar assessment of αvβ5 expression (Figure 2B) illustrates that 
expression of the integrin is highest in cell lines representative of B cell precursors and 
decreases in mature B cell lines (Figure 2B). Cell lines representing earlier stages of B 
cell development (RS4;11 and SMS-SB) have low levels of CXCR4 expression and show 
the most robust growth response following αvβ5 ligation; SDF-1 enhances αvβ5-
mediated  cell growth induced by LP in these cells (Figure 2C).  Despite higher CXCR4 
expression, SDF-1 does not affect the growth of either Blin-1 cells, which show a modest 
increase in cell growth after αvβ5 ligation (by sCD23), or Daudi cells, which show little 
or no growth response via αvβ5 (as shown by LP treatment). Finally, the cell line IB4 
which is low/negative for both CXCR4 and αvβ5 expression shows no increase in cell 
growth following αvβ5 ligation with LP in the presence or absence SDF-1 (Figure 2C).  
 
The cytokines IL-7, IL-11, IL-3 and IL-4 were also assessed to determine if any of them 
could enhance αvβ5-induced cell growth; none of these cytokines mimicked the ability of 
SDF-1 to enhance αvβ5-mediated cell growth (Figure 3).  IL-7 has no effect on LP-
induced SMS-SB cell growth (Figure 3A), and while IL-11 alone induces an increase in 
[3H]-TdR incorporation (Figure 3B) it has no effect on αvβ5-regulated cell growth; 
neither IL-3 nor IL-4 enhances αvβ5-induced growth (Figure 3C and 3D). Growth 
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responses to the different cytokines were tested using all of the different αvβ5-directed 
stimuli and none of the cytokines tested modulated αvβ5 expression (data not shown).  
 
 
SDF-1 enhances ERK phosphorylation induced by sCD23 and other αvβ5 ligands 
 
The signalling pathways that might regulate synergistic activation of cell growth by αvβ5 
ligation and SDF-1 treatment were evaluated, with a focus on ERK phosphorylation since 
SDF-1 is known to target this pathway (41). Treatment of SMS-SB cells with sCD23 
promotes robust phosphorylation of ERK at 30-60min (Figure 4A). SDF-1 alone 
provokes an early, modest increase in phospho-ERK levels (Figure 4A).  By contrast, co-
stimulation of SMS-SB cells with SDF-1 and sCD23 stimulates a very robust ERK 
phosphorylation that is sustained until 10 minutes post-stimulation, yielding phospho-
ERK levels that are some 15-fold greater than either stimulus alone (Figure 4A and 4B).  
The 15F11 MAb induces ERK phosphorylation at 10-30 min post-stimulation, while co-
stimulation with SDF-1 and 15F11 promotes an earlier onset of ERK phosphorylation 
that is sustained to 30 min (Figure 4C).  The RKC-containing CD23-derived peptide #9 
behaves similarly, inducing a modest response by itself and a more rapid and sustained 
response when added together with SDF-1; peptide #8, which lacks the RKC motif, fails 
to induce significant phosphorylation either alone or in association with SDF-1 (Figure 
4D).  Finally, the RKC-containing pentadecameric LP induces sustained and robust ERK 
phosphorylation that is enhanced by SDF-1 co-stimulation (Figure 4E). LP has an affinity 
for αvβ5 that is an order of magnitude greater than that of CD23 itself (~ 10-7 M vs 6 x 
10-6 M) (2) and this greater affinity may explain the higher and more sustained levels of 
ERK phosphorylation noted with LP.  The data are consistent with the interpretation that 
ligation of αvβ5 by a soluble ligand alone promotes a modest level of ERK 
phosphorylation that is enhanced by SDF-1; SDF-1 also drives a more rapid elevation in 
ERK phosphorylation when added together with a soluble αvβ5 ligand.  
 
We used the MEK inhibitor U0126 and PI3K inhibitor LY294002 to further investigate 
the specificity of the ERK signalling pathway in αvβ5-mediated functions. Pre-treatment 
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of SMS-SB cells with U0126 completely abolishes the effect of sCD23 and CD23-
derived peptides on cell growth (Figure 5A).  Moreover, U0126 inhibits basal survival of 
SMS-SB cells in low-density cultures within a few hours of initiation of the culture. 
U0126 treatment also abrogates the ERK phosphorylation driven by SDF-1 or sCD23 
individually and also completely prevents the enhancement of ERK phosphorylation 
observed with SDF-1 and sCD23 co-stimulation (Figure 5C).  The PI3K inhibitor 
LY294002 also attenuates growth of SMS-SB cells in response to αvβ5 ligation, but this 
inhibition is less complete than that observed with U0126 (Figure 5B). Thus, after 48 
hours of LP stimulation a small increase in [3H]-TdR incorporation remains evident in 
cells pre-treated with LY294002, whereas no growth is detectable after 12 h of U0126 
treatment (Figure 5A and 5B).  Analysis of SMS-SB cell survival using annexinV/ 
propidium iodide (AV/PI) staining demonstrated that U0126 treatment results in a higher 
proportion of AV/PI double-positive cells than LY294002 treatment after a 12 h period 
(Figure 5D), illustrating that U0126 leads to increased apoptosis in SMS-SB cells relative 
to LY294002 treatment. This underscores the importance of the ERK signalling pathway 
in the survival of SMS-SB cells. 
 
 
PDGF enhances αvβ5-driven growth of pre-B cell lines 
 
PDGF stimulates SMS-SB cell growth and the cells express PDGF receptor β (PDGFRβ) 
(48). Figure 6A and 6B, respectively, show that PDGF-β significantly enhances both LP- 
and sCD23-induced growth of SMS-SB cells. As observed with SDF-1, PDGF treatment 
does not alter surface expression of αvβ5 (Figure 6C) and, furthermore, the increase in 
[3H]-TdR incorporation promoted by sCD23 and PDGF treatment correlates well with 
enhancement in ERK phosphorylation.  Stimulation of SMS-SB cells with PDGF alone 
results in significant ERK phosphorylation, and co-stimulation with PDGF and sCD23 
strikingly enhances this ERK phosphorylation (Figures 6D). 
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Response of normal bone marrow B cells and ALL cells to soluble αvβ5-specific 
stimulation 
 
B cell precursors from the bone marrow that are positive for αvβ5 integrin also express 
CXCR4 and cells from patients with ALL also express the αvβ5 integrin and CXCR4. 
Growth of BM-derived B cell precursors and ALL cells was investigated in order to 
relate the data from pre-B cell lines with their normal and malignant counterparts in the 
bone marrow.  The ability of CD19+ / κ- FACS-sorted B cell precursors isolated from 
bone marrow aspirates to respond to stimulation with soluble αvβ5-directed ligands was 
assessed.  A robust incorporation of thymidine was stimulated by both LP (5μg/ml) and 
by sCD23 (250ng/ml) (Figure 7A) while a control peptide devoid of the RKC motif, 
peptide #8, was without effect; the cells also responded to the 15F11 MAb indicating the 
specificity of αvβ5 integrin in mediating cell growth (data not shown). Secondly, both 
sCD23 and LP promote growth of ALL cells (αvβ5+ see supplementary Figure 3) above 
background levels (Figure 7B) and co-stimulation with SDF-1 (Figure 7C) or PDGF 
(Figure 7D) with lower concentrations of sCD23 resulted in significant enhancement in 
cell growth.  The data demonstrate that normal bone marrow-derived B cell precursors 
and patient-derived ALL cells can respond to sCD23 and related ligands. The growth 
responses were not as robust as those noted in the cell line models and although we 
observed enhancement in cell growth with the addition of SDF-1 and PDGF, the [3H]-
TdR incorporation induced by suboptimal concentration of sCD23 in these cases was 
minimal.  
 
 
Discussion  
 
It is well established that chemokines dynamically regulate the positioning of cells of the 
immune system by influencing the structure of integrin molecules to ensure that cells 
attracted to a specific niche are retained there via adhesion reactions with tissue matrix 
proteins. Chemokines can also positively influence signalling via integrins in such 
adhesion-dependent interactions, as exemplified by the action of SDF-1 on 
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haematopoietic precursors at the level of the VLA-4-ICAM1 interaction (31, 32).  This 
report demonstrates that SDF-1 positively influences signalling events delivered to 
integrins in a soluble, adhesion-independent manner. Thus, ligation of αvβ5 using 
specific MAbs, sCD23 or peptides derived from sCD23 provokes ERK phosphorylation 
and growth responses in B cell precursors that are enhanced by SDF-1. PDGF also 
enhances signalling delivered via soluble ligation of αvβ5, suggesting that both tyrosine 
kinase and G protein-coupled receptor-linked pathways modulate adhesion-independent 
signalling by αvβ5. 
 
Growth of SMS-SB cells stimulated with sCD23 was enhanced by addition of SDF-1 and 
similar responses were noted with sCD23-derived peptides (containing the RKC motif 
recognised by αvβ5) and the anti- αvβ5 MAb 15F-11, all of which promote growth of 
these cells.  SDF-1 acts through CXCR7 as well as via CXCR4 and in order to address 
the specificity of CXCR4 in enhancing αvβ5-mediated signals, the binding of SDF-1 to 
CXCR4 was blocked using the CXCR4 antagonist AMD3100 (49, 50).  AMD3100 
completely abolished the ability of SDF-1 to enhance αvβ5-mediated SMS-SB cell 
growth (Figure 1F); pre-treatment of SMS-SB cells with the anti-CXCR4 MAb (12G5) 
also inhibited the action of SDF-1 (data not shown). There is growth of SMS-SB cells 
with AMD3100 treatment alone (Figure 1F). AMD3100 has been extensively used as 
CXCR4 antagonist however it has also been suggested to be a weak partial agonist (51), 
which might partly explain the small apparent growth effect with AMD3100 alone.  
However, in the presence of SDF-1, AMD3100 clearly acts as a CXCR4 antagonist.  
Importantly, AMD3100 has no effect on LP-induced cell growth but blocks the 
enhancement in growth with LP and SDF-1. Finally, assessment of expression of CXCR7 
expression illustrated that SMS-SB cells have modest level of CXCR7, Blin-1 cells have 
no CXCR7 but express CXCR4, while IB4 cells lack CXCR4 but express CXCR7; IB4 
cells do not respond to SDF-1 stimulation (data not shown).  Taken together the data are 
consistent with the interpretation that SDF-1 mediates its effect on αvβ5-stimulated cell 
growth via CXCR4.   
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Higher levels of CXCR4 expression do not influence the lack of response to αvβ5 
ligation noted in the more mature cell lines, and this is consistent with data showing that 
although B-cell precursors express higher levels of CXCR4 with increasing maturation, 
the cells chemotactic response to SDF-1 itself is apparently blunted.  Thus, CXCR4 is 
continuously expressed by B cells and, as the cells mature and begin to express surface 
IgM, the chemotactic response to SDF-1 is lost despite sustained expression of CXCR4 
(52-54).  In agreement with these results our data support the notion that αvβ5-mediated 
cell growth is important at particular stages of B cell development and is modulated by 
SDF-1 in a stage-specific manner.  
 
SMS-SB cells undergo apoptosis in low-density culture conditions (3).  The inhibition of 
cell growth by U0126 shows that basal ERK phosphorylation is necessary for the survival 
of SMS-SB cells; in the presence of U0126 the cells rapidly undergo apoptosis. ERK 
phosphorylation observed following sCD23, RKC-containing peptide or 15F-11 
treatment demonstrates that growth induced by ligation of αvβ5 with sCD23 is regulated 
via the ERK signalling pathway. The enhancement in cell growth noted with SDF-1 and 
sCD23 correlated well with a sustained increase in ERK phosphorylation.  This was 
verified by similar enhancements observed when CD23-derived peptides and 15F-11 
antibody were used as stimuli. However it cannot be excluded that other signalling 
pathways might be involved in regulating SMS-SB cell growth, and the observation that 
LY294002 inhibited the enhancement of αvβ5 -mediated cell growth by SDF-1 indicates 
that AKT has the potential to regulate adhesion-independent signalling by αvβ5. This 
would be consistent with studies that demonstrate that SDF-1 activates both ERK and 
AKT (38, 55, 56) and merits further investigation.  
 
Many cytokines are known to modulate integrin function and B-cell precursor survival, 
but no similar enhancement of αvβ5-mediated cell growth was promoted by the 
cytokines IL-7, IL-3, IL-4 and IL-11 at the concentrations used.  It has been shown that 
SDF-1, IL-3 and IL-7 induce proliferation of ALL cells co-cultured with stromal cells; 
IL-7 alone did not induce ERK activation but there was a synergistic ERK activation 
following IL-7 and SDF-1 co-stimulation (57). However, in the co-culture studies, the 
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ALL cells were propagated on stromal cells and effects on ERK and other signalling 
pathways would have been affected by multiple adhesion contacts between the ALL cells 
and stromal cells. Therefore, the data from the ALL-stromal cell co-culture model 
illustrate convincingly that ERK phosphorylation can occur in an adhesion-dependent 
manner (57).  
 
In our own studies of normal bone marrow B cells and ALL-derived cells, cultures that 
lacked serum or stromal cell support failed to support any growth of the cells. Using bone 
marrow B cell precursors propagated on irradiated stromal cells we were able to show 
that αvβ5 ligation by sCD23 induces growth response in these precursors, similar to that 
seen in cell lines. The importance of this was further assessed in ALL cells to investigate 
if SDF-1 could enhance this αvβ5-mediated growth response.  Cultures with stromal cells 
supported modest growth of ALL cells exposed to αvβ5-stimulatnts alone and some 
degree of enhancement of sCD23-driven growth of ALL cells by SDF-1 was achieved. 
The data indicate that normal marrowcytes respond to sCD23 and that in ALL cells some 
additive effect of αvβ5-directed ligands and other receptors can be elicited. The finding 
that sCD23 can induce ERK phosphorylation in B cell precursor cell lines is consistent 
with data from studies of monocytes that showed strong ERK responses to  integrin 
ligation and sCD23 stimulation (58, 59), and it remains to be determined whether sCD23 
and other αvβ5 ligands can induce ERK phosphorylation in normal B cell precursors and 
ALL cells. 
 
Finally, PDGF enhanced the cell growth induced via αvβ5 in a manner similar to that 
observed with SDF-1. Interestingly, a previous study shows that early pre-B cells, but not 
mature B cells, express the PDGFRβ and PDGF was shown to promote proliferation of 
these cells but not immature B cells (60). A number of studies, particularly in adherent 
cell systems, have demonstrated a cross-talk between growth factors and integrin 
signalling, and synergy between growth factors and cell adhesion has been observed in 
the activation of the MAPK (61, 62) and PI3K/AKT pathways (63). Moreover, PDGF has 
previously been shown to interact physically with the αvβ3 integrin to stimulate 
proliferation of oligodendrocytes by activation of the integrin in an adhesion-dependent 
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manner (64). Therefore, it is plausible that PDGF and αvβ5 also interact to promote 
adhesion-independent proliferation in B cell precursors.  Our data indicate that αvβ5 
synergises with two distinct signalling pathways, via a tyrosine kinase receptor (PDGFR-
β) and a G protein-coupled receptor (CXCR4), to promote ERK phosphorylation and pre-
B cell growth. It will be important to determine the common molecules downstream of 
both these pathways leading to ERK phosphorylation in order to understand further the 
mechanisms involved in αvβ5 -mediated cell growth.  
 
The model emerging from these data suggests a role for αvβ5 integrin in B cell precursor 
survival and growth that can be modulated by other biological effectors such as SDF-1 
and PDGF. This may have important implications for growth of normal and neoplastic B 
cells. B cell development in different compartments of the hematopoietic 
microenvironment is accompanied by stage-specific changes that are critical for 
proliferation and differentiation into later developmental stages. A range of adhesion and 
signalling molecules controlling each stage are not only key to understanding the 
progression into the developmental pathway but also in developing therapies for 
neoplasias that arise in different stages of B-cell development.  
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Figure 1: SDF-1 enhances αvβ5 -mediated growth of SMS-SB cells.  
(A) Low cell density (LCD) cultures of SMS-SB cells were propagated with the indicated 
concentrations of recombinant sCD23, and [3H]-TdR incorporation assessed after 72hr. 
(B) Growth of LCD cultures of SMS-SB cells in response to a sub-optimal concentration 
of sCD23 (158ng/ml) together with indicated concentrations of SDF-1 (black bars) and 
SDF-1 alone (hatched bars) is shown. Panels C-E illustrate the growth response of SMS-
SB cells to stimulation with 5µg/ml 15F-11 MAb (C), 5µg/ml peptide #9 (D), and 1µg/ml 
long peptide (LP) (E), respectively, in combination with SDF-1. In each panel, the 
treatment with SDF-1 alone is shown as a hatched bar, the combination of SDF-1 and 
stimulus as a black bar, and the combination of SDF-1 with either isotype control IgG2a 
(C) or irrelevant peptide #34 (D) shown as a white bar. Figure 1F represents growth with 
a sub-optimal concentration of LP (1µg/ml) and SDF-1 (250ng/ml) in untreated cells and 
cells treated with 50µM AMD3100 for 30 min prior to SDF-1 addition. In both cases, no 
stimulus is represented as grey bars, LP treatment is represented as black bars, the LP and 
SDF-1 combination as white bars and SDF-1 alone as hatched bars. Bars represent the 
standard deviation of triplicate determinations. On the figures, *p<0.05 or **p<0.01 
indicate the statistical significance of the increase in growth of cells treated with different 
concentrations of SDF-1 and αvβ5 stimulants (sCD23, 15F-11MAb, peptide #9 or LP) in 
comparison to SDF-1 treatment alone,  #p<0.05 and ##p<0.01 indicate the significance in 
enhancement of proliferation with 250ng/ml SDF-1 and αvβ5 stimulants when compared 
with αvβ5 stimulants alone. Data are representative of three independent experiments. 
(G) SMS-SB cells cultured in the presence or absence of 250ng/ml SDF-1 (24 h) were 
stained for αvβ5 expression using the anti- αvβ5 MAbs P1F-6 and 15F-11. Fluorescence 
intensity histograms for the relevant αvβ5 MAb are represented by the grey shaded area 
and isotype control antibody staining is represented by the black line. 
 
 
 
Figure 2:  Levels of CXCR4 expression do not influence cell growth  
Panels A and B show staining of CXCR4 (12G5) and αvβ5 (P1F6) respectively, in five 
cell lines.  Antibody staining is shown in the grey shaded area and the isotype control 
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staining by the black line. (C) In the different cell lines shown, [3H]-TdR incorporation 
driven by αvβ5 ligation (either with 2ng/ml sCD23 or with 1µg/ml LP) and SDF-1 is 
shown by black bars, and the growth response induced with SDF-1 alone is shown as 
hatched bars. Bars represent the standard deviation of triplicate determinations; *p<0.05 
or **p<0.01   indicates a statistically significant different increase in growth of cells 
treated with different concentrations of SDF-1 and αvβ5 stimulants (sCD23 or LP) in 
comparison to SDF-1 treatment alone, and #p<0.05 and ##p<0.01 indicates a significant 
enhancement of cell growth with 250ng/ml SDF-1 and αvβ5 stimulants when compared 
with αvβ5 stimulants alone. Data are representative of three independent experiments. 
 
 
Figure 3: Regulation of αvβ5-mediated cell growth by other cytokines.  
Figures 3A, B, C and D represent growth of LCD cultures of SMS-SB cells in response 
to 1µg/ml LP or 5µg/ml peptide #9, together with the indicated concentrations of IL-7, 
IL-11, IL-3 and IL-4, respectively. In each case, growth induced by the peptides and the 
cytokine is shown in black bars, by cytokine alone is shown as hatched bars and by 
cytokine with negative control peptide # 41 or #8 is shown as white bars. The 
concentrations of each cytokine are equivalent molar concentrations. Data are 
representative of three independent experiments. 
 
Figure 4:  SDF-1 enhances ERK phosphorylation in cells treated with αvβ5 ligands.  
Lysates from treated SMS-SB cells were separated by SDS-PAGE and transferred to 
nitrocellulose. Membranes were probed with antibodies to phosphorylated ERK and 
subsequently stripped and reprobed with antibodies to total protein (either ERK or actin). 
Panel A shows western blots of phosphorylated and total ERK in untreated SMS-SB 
cells and cells treated with sCD23 (160ng/ml), SDF-1 (250ng/ml) or a combination of 
sCD23 and SDF-1, at the time points shown. (B) The increase in phosphorylation was 
quantitated by densitometric analysis of the bands. Panel C represents western blots for 
phosphorylation of ERK and for total actin in SMS-SB cells treated with 15F-11 MAb 
alone or in combination with SDF-1. (D) Western blots for phosphorylated and total ERK 
in SMS-SB cells treated with peptide #9 (5µg/ml), negative control peptide #8 (5µg/ml). 
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Panel E represents western blots for phosphorylation of ERK and for total actin in SMS-
SB cells treated with LP (1µg/ml) alone or in combination with SDF-1.  
 
Figure 5: Effect of inhibition of ERK and PI-3K signalling on αvβ5-mediated 
growth of SMS-SB cells.  
SMS-SB cells were treated with 10µM U0126 or 50µM LY294002 or left untreated for 
30 min prior to plating at LCD; cell growth was assessed by [3H]-TdR incorporation after 
72 h of culture. Panel A shows cell proliferation with LP and/or SDF-1 in untreated cells 
and cells treated with U0126. Panel B shows cell growth stimulated by LP and/or SDF-1 
in untreated cells or cells treated with LY294002. Unstimulated cells are represented as 
grey bars, LP treated as black bars, the LP and SDF-1 combination as white bars and 
SDF-1 treatment alone as hatched bars. Bars represent the standard deviation of triplicate 
determinations, with *p<0.05 or **p<0.01 indicating a statistically significant increase in 
proliferation of cells treated with different concentrations of SDF-1 and αvβ5 stimulants 
(LP) in comparison to SDF-1 treatment alone; #p<0.05 and ##p<0.01 denote the 
significance of enhancement in cell growth with 250ng/ml SDF-1 and αvβ5 stimulants 
when compared with αvβ5 stimulants alone. Data are representative of three independent 
experiments. Panel C illustrates western blot analysis of phosphorylated ERK and total 
actin in SMS-SB cells pre-treated with 10µM U0126, 30 min before stimulation with 
SDF-1 (250ng/ml) or sCD23 (160ng/ml) or a combination of SDF-1 and sCD23. Panel D 
shows contour plots for PI/annexinV staining of cells exposed to 10µM U0126, 50µM 
LY294002, DMSO (vehicle) or no treatment for 12 h. Quadrant gates in the insets are  
based on unstained, annexinV or PI stains alone. 
 
 
Figure 6: PDGF enhances αvβ5 -driven growth and ERK phosphorylation in SMS-
SB cells.  
LCD SMS-SB cultures were stimulated with the indicated concentrations of PDGFβ and 
1µg/ml LP (Panel A) or 160ng/ml sCD23 (Panel B) for 72 h prior to determination of 
[3H]-TdR incorporation. Growth induced by PDGF and LP or sCD23 in combination 
with PDGF is shown as black bars and that driven by PDGF alone is shown as hatched 
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bars. Bars represent the standard deviation of triplicate determinations, with *p<0.05 or 
**p<0.01 indicating the statistical significance of the increase in growth of cells treated 
with different concentrations of SDF-1 and αvβ5 stimulants (sCD23 or LP) in 
comparison to SDF-1 treatment alone, #p<0.05 and ##p<0.01 indicate the significance of 
the enhancement of cell growth with 250ng/ml SDF-1 and αvβ5 stimulants when 
compared with αvβ5 stimulants alone. (C) SMS-SB cells untreated or treated with 
250ng/ml PDGF (24 h) were stained for αvβ5 expression using the anti- αvβ5 MAbs 
P1F-6 and 15F-11. Staining with the relevant αvβ5 MAbs is represented by the grey 
shaded area and isotype control antibody staining is represented by the black line. Panel 
D shows western blots for phosphorylated ERK and ERK2 in SMS-SB cells treated with 
PDGF (250ng/ml) alone or PDGF (250ng/ml) with sCD23 (160ng/ml).  
 
 
Figure 7.  Response of Normal B cell precursors and ALL Cells to αvβ5 Ligands 
Aliquots of κ- FACS-sorted human bone marrow B cells (Panel A) or cells derived from 
samples from ALL patients (Panel B) were stimulated with 5µg/ml peptide #8, LP or 
with 250ng/ml sCD23 for 48 hr prior to pulse with tritiated thymidine.  Aliquots of ALL 
cells were also stimulated with 150ng/ml sCD23 in the presence or absence of 250ng/ml 
SDF-1 (Panel C) or PDGF (Panel D), prior to assessment of cell growth. Bars represent 
the standard deviation of triplicate determinations, with *p<0.05. 
 
 
Supplementary Figure 1 
Panel A:- SMS-SB cells were incubated overnight in the presence or absence of SDF-1 
then treated with CD23-derived, RKC-containing biotinylated peptide #9 or #11, or with 
peptide #41 that lacks RKC,  and binding visualized using PE-streptavidin as described 
previously (2).  The upper pair of panels shows staining of untreated SMS-SB cells, while 
the lower two panels show the equivalent staining of SDF-1-treated cells; the solid black 
line shows staining with peptide #41 while the filled grey area illustrates staining with the 
RKC peptides  #9 or #11. 
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Panel B:-  SMS-SB cells were stimulated with LP or sCD23 or peptide #8, which lacks 
the RKC motif, as described in the legend to Figure 1 and stained with biotinylated-12G5 
anti-CXCR4 antibody; binding was visualized with PE-streptavidin.  For each indicated 
treatment, the histograms show background staining with IgG2a immunoglobulin as a 
black line and staining with 12G5 in the filled grey area. 
 
 
 
 
 
 
 
 
  
 

 

 
 
